Displaying 172 (all) recruiting clinical trials.
-
AALL1821: A Phase 2 Study of Blinatumomab (NSC# 765986 IND# 125462) in Combination with Nivolumab (NSC# 748726 IND# 125462) a Checkpoint Inhibitor of PD-1 in B-ALL Patients Aged >/=1 to
The purpose of the study is to study the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell ...
Phase
Interventional
-
Pan Tumor Study for Long-term Treatment of Cancer Patients Who Have Participated in BMS sponsored Trials Investigating Nivolumab and Other Cancer Therapies
This is a Phase 2, open-label, pan tumor trial which enrolls participants from ongoing companysponsored studies (Bristol-Myers Squibb Company [BMS] Parent Studies) that evaluated nivolumab ...Phase
Interventional
-
A Phase 1 Open-Label Study to Evaluate the Safety Tolerability Pharmacokinetics and Efficacy of BL-M07D1 in Subjects with HER2 Expressing Advanced Malignant Solid Tumors
This is a multicenter Phase 1 study evaluating the safety, tolerability, pharmacokinetic (PK) profile, and initial efficacy of BL-M07D1 in subjects with metastatic or unresectable ...Phase
Interventional
-
A Phase I/IIa Dose Escalation Study Evaluating the Safety Tolerability and Preliminary Efficacy of Intraductal Administration of RXRG001 to Parotid Gland(s) in Adults with Radiation-Induced Xerostomia and Hyposalivation
This is a Phase 1/2a study testing whether administering the new study medicine RXRG001 (a lipid nanoparticle containing circular mRNA) directly into the ducts ...
Phase
Interventional
-
A PHASE 0/I STUDY TO ASSESS THE SAFETY AND TOLERABILITY OF XRD-0394 IN COMBINATION WITH RADIATION THERAPY IN PATIENTS WITH HIGH GRADE GLIOMAS
This is an open-label, dose-finding study of XRD-0394 in subjects with newly diagnosed and recurrent high grade gliomas receiving radiation therapy, with and without concurrent ...Phase
Interventional
-
A Randomized Open-label Multicenter Phase 2 Study Evaluating the Efficacy and Safety of Zilovertamab Vedotin (MK-2140) Plus R-CHP Versus Polatuzumab Vedotin Plus R-CHP in Treatment-na ve Participants With GCB Subtype of Diffuse Large B-cell Lymphoma (DLBCL)
This is a Phase 2 study testing two different medicines to treat a blood cancer called GCB DLBCL(diffuse large B-cell lymhoma). Zilovertamab Vedotin (an ...
Phase
Interventional
-
A Phase 1b/2 Study of Immune and Targeted Combination Therapies in Participants with RCC (KEYMAKER-U03): Substudy 03C in Participants With Recurrent Disease During or After Anti-PD-(L)1 Adjuvant Therapy
Despite clear advances that have been taking place in the treatment of advanced RCC in recent years, there are still unmet medical needs and opportunities ...Phase
Interventional
-
A Randomised Open-Label Phase III Study of Saruparib (AZD5305) Plus Camizestrant compared with Physician's Choice CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant for the First-Line Treatment of Patients With BRCA1 BRCA2 or PALB2 Mutations and Hormone Receptor Positive HER2-Negative (IHC 0 1+ 2+/ ISH non-amplified) Advanced Breast Cancer (EvoPAR-Breast01)
This study is testing how well a new medicine, saruparib (AZD5305), works when combined with camizestrant compared to other common treatments for advanced breast cancer ...
Phase
Interventional
-
Expanded Access Treatment of Neladalkib (NVL-655) in Patients with Advanced ALK+ NSCLC or Other ALK+ Solid Tumors
This is a study testing a medicine called Neladalkib (a type of ALK blocker) for patients who have ALK-positive non-small cell lung cancer (NSCLC) that ...
Phase N/A Interventional
-
Global Phase 3 Randomized Open-Label Study to Evaluate Efficacy & Safety of Firmonertinib Comp.w/ Osimertinib or Afatinib as 1st line Treat. in Pts. w/ Locally Advanced or Metastatic NSCLC with EGFR PACC Uncommon Mutations (Alpacca)
This is a Phase 3 study testing the safety and effectiveness of the new medicine firmonertinib (an EGFR-tyrosine kinase inhibitor) and comparing it with standard ...
Phase
Interventional
